Navigation Links
Scientists discover cells critical to childhood leukemia
Date:1/21/2010

Scientists at The Royal Melbourne Hospital and the University of Melbourne in Australia have discovered the cells that cause a common type of childhood leukaemia T cell Acute Lymphoblastic Leukaemia (T-ALL). Targeting of these cells may lead to improved treatments for this disease and help prevent relapse.

The team, led by Dr Matthew McCormack and Dr David Curtis of the Rotary Bone Marrow Research Laboratories and the University's Department of Medicine at The Royal Melbourne Hospital, made the discovery whilst studying mice prone to developing this leukaemia.

The results have been published online today by the prestigious international journal Science.

The team found that with irradiation treatment in animal models, over 99 per cent of cells in the thymus were killed, but these stem cell-like cells persisted and rapidly recovered. This suggests that these cells may survive therapy and be responsible for relapsed disease following treatment.

Currently, children with T-ALL are given extended therapy over two to three years in an attempt to stop a relapse. More targeted therapy on the thymus cells could reduce the length and toxicity of treatment and prevent relapse.

Dr McCormack, a leading international expert on childhood leukaemia, said: "The cellular origins of this leukaemia are not well understood. Our discovery that these cells are similar to normal stem cells explains why they are capable of surviving for long periods. It also explains why they are remarkably resistant to treatment."

Approximately 50 new cases of T-ALL are diagnosed every year in Australia, two thirds of these in children or adolescents. Adults also contract T-ALL, and the majority succumb to resistant or relapsed disease.

Dr Curtis, a Clinical Haematologist and head of the Leukaemia Research Program at The Royal Melbourne Hospital, said: "The identification of these cells provides an important target for the development and testing of new treatments for patients with T cell Acute Lymphoblastic Leukaemia."

The team will now focus on novel treatments capable of killing these cells, which may lead to clinical trials within the next five years.


'/>"/>

Contact: Rebecca Scott
rebeccas@unimelb.edu.au
61-383-440-181
University of Melbourne
Source:Eurekalert

Related medicine news :

1. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
2. Scientists Probe Sepsis Deadly Secrets
3. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
4. Scientists Develop Natural Protection for Stored Foods
5. Scientists detect presence of marburg virus in african fruit bats
6. Scientists Spot Brains Free Will Center
7. Scientists ID Likely Culprit in Popcorn Lung
8. Scientists explain how insulin secreting cells maintain their glucose sensitivity
9. Scripps Research scientists shed new light on how antibodies fight HIV
10. Scientists, physicians present latest findings in personalized cancer treatment and prevention
11. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... ... August 24, 2017 , ... Lori ... the development and advances in Desensitization therapy to improve the outcomes of organ ... about his remarkable journey of his 25 years of research in developing therapies ...
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home ... have a condition that needs further monitoring such as surgery, stroke, heart attack ... stable, such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. ...
(Date:8/23/2017)... ... 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs and ... community organization for people with special needs. The group, the Special Needs Alliance for ... of New Jersey – but the first in the entire country! , SNAP was ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
(Date:8/23/2017)... ... ... Awards have announced the winners of the Best of the IBA Awards in The 2017 ... in the 2017 IBAs were not able to apply for the Best of the IBA ... awards won in the IBAs with a Gold Stevie win counting for three points, a ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017   Mostyn Law and Gulf Coast Regional Blood ... . The Mostyn Law family has had 3 ... is why Mostyn Law is partnering with Gulf Coast ... its appreciation. Blood supplies are running low. Gulf Coast ... hospital needs in August. That is why the blood center reached ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology: